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Chronic	  hepatitis	  C	  Virus	  (HCV)	  infection	  causes	  liver	  disease	  and	  may	  progress	  to	  severe	  fibrosis,	  
cirrhosis,	  and	  hepatocellular	  carcinoma.	  This	  thesis	  aimed	  to	  evaluate	  the	  impact	  of	  host	  genetics,	  i.e.	  
genetic	  variants	  of	  PNPLA3,	  IL28B	  and	  ITPA,	  on	  liver	  disease	  severity	  and	  treatment	  outcome	  in	  HCV	  
genotype	  2	  and	  3	  infected	  patients	  treated	  with	  pegylated	  interferon	  and	  ribavirin	  for	  either	  12	  or	  24	  
weeks.	  
In	  paper	  I,	  359	  patients	  were	  evaluated	  retrospectively	  with	  regards	  to	  the	  impact	  of	  the	  PNPLA3	  
genetic	  variants.	  No	  significant	  impact	  was	  observed	  on	  liver	  disease	  severity	  nor	  on	  treatment	  
outcome,	  and	  the	  clinical	  need	  to	  screen	  Nordic	  HCV	  genotype	  2	  or	  3	  infected	  patients	  for	  these	  
genetic	  variants	  seems	  low.	  	  
In	  papers	  II	  and	  III,	  in	  post-­‐hoc	  evaluation	  encompassing	  339	  Nordic	  HCV	  genotype	  2	  or	  3	  infected	  
patients,	  genetic	  variants	  of	  the	  rs12979860	  in	  proximity	  to	  IL28B	  were	  not	  associated	  with	  
treatment	  outcome	  but	  the	  CCrs12979860	  and	  the	  TTrs8099917	  genetic	  variants	  (n=314)	  were	  found	  to	  be	  
associated	  with	  more	  pronounced	  liver	  histopathology	  among	  HCV	  genotype	  3	  infected	  patients.	  
Thus,	  these	  patients	  may	  benefit	  from	  early	  initiation	  of	  therapy.	  
In	  paper	  IV,	  in	  a	  real	  life	  trial	  (n=737)	  enrolling	  HCV	  genotype	  1-­‐3	  infected	  patients	  evaluated	  by	  
means	  of	  transient	  elastography,	  CCrs12979860	  was	  significantly	  associated	  with	  higher	  liver	  stiffness	  
values	  among	  HCV	  genotype	  3	  infected	  patients;	  thus	  confirming	  the	  results	  of	  papers	  II	  and	  III	  in	  an	  
independent	  cohort	  of	  patients.	  
In	  paper	  V,	  in	  a	  post-­‐hoc	  analysis	  of	  Nordic	  HCV	  genotype	  2	  or	  3	  infected	  patients	  treated	  with	  800	  
mg	  ribavirin	  daily	  and	  interferon,	  reduced	  ITPase	  (n=354)	  activity	  was	  significantly	  associated	  with	  
increased	  likelihood	  of	  achieving	  sustained	  virological	  response.	  Thus	  the	  majority	  of	  patients	  having	  
normal	  ITPase	  activity	  may	  benefit	  more	  from	  a	  higher	  weight-­‐based	  dosing	  of	  ribavirin.	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